BTC

Jun 19, 2026

Summary The BTC treatment landscape is shifting from chemotherapy to precision oncology. While gemcitabine-based chemotherapy remains the backbone of first-line and advanced disease treatment, the field has increasingly moved toward biomarker-driven therapy and chemoimmunotherapy. Approved targeted therapies...

May 08, 2026

Summary BTC (including cholangiocarcinoma and gallbladder cancer) is a challenging malignancy with rising global incidence, especially in Asia and Latin America, driven by risk factors like chronic inflammation and liver flukes; ~65,000 incident cases in 7MM in 2025, projected to grow by 2036, with highest case...